Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.48 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.48 |
| ▸ | BRS3 | P32247 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.48 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.48 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.48 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.48 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.48 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.48 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.48 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.48 |
| ▸ | WDR5 | P61964 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.48 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL6864877 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29002845 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL6829013 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL142791 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL4371701 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL142905 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL2484203 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL1292977 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL2516725 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL18951954 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842953-A1 | Process for the preparation of esomeprazole magnesium dihydrate | Cipla Limited (IN) | 2015-03-04 | — | — | EP | claimed |
| EP-2186807-B1 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LTD (IN) | 2015-01-07 | — | — | EP | claimed |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | claimed |
| US-8394963-B2 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LIMITED (IN) | 2013-03-12 | — | — | US | claimed |
| EP-2186807-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | Cipla Ltd. (IN) | 2010-05-19 | — | — | EP | claimed |
| US-20100113526-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | claimed |
| EP-2125783-A2 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE | Cipla Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008102145-A2 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE | CIPLA LIMITED (IN) | 2008-08-28 | — | — | WO | claimed |
| EP-2842953-A1 | Process for the preparation of esomeprazole magnesium dihydrate | Cipla Limited (IN) | 2015-03-04 | — | — | EP | disclosed |
| EP-2186807-B1 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LTD (IN) | 2015-01-07 | — | — | EP | disclosed |
| CN-102159567-B | Process for the preparation of esomeprazole magnesium in a stable form | LEK PHARMACEUTICALS | 2014-08-06 | — | — | CN | disclosed |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| US-8394963-B2 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LIMITED (IN) | 2013-03-12 | — | — | US | disclosed |
| US-6713495-B1 | FORMING ORGANIC SOLVENT FREE FORM; FLASH EVAPORATING | Sherman, Bernard Charles (CA) | 2004-03-30 | — | — | US | disclosed |
| WO-2004002982-A2 | A PROCESS FOR PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED SULFOXIDE COMPOUNDS, INCLUDING AMORPHOUS ESOMEPRAZOLE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-01-08 | — | — | WO | disclosed |
| EP-1375497-A1 | Magnesium salt of s-omeprazole | Sherman, Bernard Charles (CA) | 2004-01-02 | — | — | EP | disclosed |
| US-20030232861-A1 | Magnesium salt of S-omeprazole | SHERMAN BERNARD CHARLES (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1230237-A1 | MAGNESIUM OMEPRAZOLE | SHERMAN, Bernard Charles (CA) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036409-A1 | MAGNESIUM OMEPRAZOLE | SHERMAN BERNARD CHARLES (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113526-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CYP2D6, TPMT, CYP3A4 | ATP4A 247/4885ATP4B 246/4885BRS3 1159/4885 |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CYP2D6, TPMT, CYP3A4 | ATP4A 247/4885ATP4B 246/4885BRS3 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.